Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two-, four- and six-month-old infants with combination Haemophilus influenzae type B/hepatitis B vaccine

Pediatric Infectious Disease Journal

Volumn 16, Issue 7, 1997, Pages 675-679

  Halsey, Neal A ^a   Blatter, Mark ^b   Bader, Gerald ^c   Thoms, Mary Lou ^a   Willingham, Field F ^a   O'Donovan, J Crossan ^d   Pakula, Lawrence ^e   Berut, Florence ^f   Reisinger, Keith S ^b   Meschievitz, Carlton ^f  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Pittsburgh Pediatric Research   (United States)

^c Vancouver Clinic   (United States)

^d Drs O'Donovan Ahluwalia Fertsch   (United States)

^e Priv Pract: Drs Pakula D   (United States)

^f Pasteur Merieux Connaught   (United States)

Author keywords

Combination vaccines; Inaetivated poliovirus vaccine; Oral poliovirus vaccine

Indexed keywords

BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; INACTIVATED VACCINE; IPOL; MEASLES MUMPS RUBELLA VACCINE; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MIXTURE; FEMALE; FEVER; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B VIRUS; HUMAN; IMMUNOGENICITY; INFANT; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

FEMALE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; INFANT; MALE; POLIOVIRUS VACCINE, INACTIVATED; POLYSACCHARIDES, BACTERIAL; VACCINES, INACTIVATED;

EID: 17344395367     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199707000-00010     Document Type: Article

References (21)

1. Recommendations of the Immunization Practices Advisory Committee. Poliomyelitis prevention: enhanced-potency inactivated vaccines - supplementary statement. MMWR 1987; 36:795-8.
2. Strebel PM, Sutter RW, Cochi SL. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992;14:568-79.
3. de Quadros CA, Hersh BS, Olivé JM, Andrus JK, da Silveira CM, Carrasco PA. Eradication of wild poliovirus from the Americas: acute flaccid paralysis surveillance, 1988-1995. J Infect Dis 1997;175(Suppl 1):S37-42.
4. Hull HF, Birmingham ME, Melgaard B, Lee JW. Progress toward global polio eradication. J Infect Dis 1997;175(Suppl 1):S4-9.
5. Cochi SL, Hull HF, Sutter RW, Wilfert CM, Katz SL. Commentary: the unfolding story of global poliomyelitis eradication. J Infect Dis 1997;175(Suppl 1):S1-3.
6. Committee on Infectious Disease American Academy of Pediatrics. Recommended childhood immunization schedule: United States, January-December 1997. Pediatrics 1997;99: 136-8.
7. Committee on Infectious Disease American Academy of Pediatrics. Poliomyelitis prevention: recommendations for use of inactivated poliovirus vaccine and live oral poliovirus vaccine. Pediatrics 1997;99:300-5.
8. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(No. RR3):1-25.
9. McBean AM, Modlin JF. Rationale for the sequential use of inactivated poliovirus vaccine and live attenuated oral poliovirus vaccine for routine use in the United States. Pediatr Infect Dis J 1987;6:881-7.
10. Institute of Medicine. An evaluation of poliomyelitis vaccine policy options. Washington, DC: National Academy of Sciences, 1988.
11. Meschievitz C, Blatter M, Starr S, Fritzell B. Safety and immunogenicity of IPV only or a sequential schedule of IPV (given separately or in combination with DTP) followed by OPV [Abstract]. Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September 15 to 18, 1996.
12. Sawyer LA, McInnis J, Patel A, Horne AD, Albrecht P. Deleterious effect of thimerosal on the potency of inactivated poliovirus vaccine. Vaccine 1994;12:851-6.
13. Pichichero ME, Francis AB, Blatter MM, Reisinger KS, Green JL. Acellular pertussis vaccination of 2 month old infants in the United States. Pediatrics 1992;89:882-7.
14. Manclark CR, Meade, BD. Serological response to Bordetella pertussis. In: Rose NR, Friedman H, eds. Manual of clinical immunology. 2nd ed. Washington, DC: American Society for Microbiology, 496-9.
15. Albrecht P, van Steenis G, van Wezel AL, Salk J. Standardization of poliovirus neutralizing antibody tests. Rev Infect Dis 1984;6:S5:40-4.
16. Committee on Infectious Diseases, American Academy of Pediatrics. Administration of the third dose of oral poliomyelitis vaccine at 6 to 18 months of age. Pediatrics 1994;94:774-5.
17. Modlin JF, Halsey NA, Thorns ML, Meschievitz CK, Patriarca PA. Humoral and mucosal immunity in infants induced by three sequential IPV-OPV immunization schedules. J Infect Dis 1997;175(Suppl 1):S228-34.
18. Patriarca PA, Sutter RW, Oostvogel PM. Outbreaks of paralytic poliomyelitis, 1976-1995. J Infect Dis 1997(Suppl 1):S165-72.
19. Vidor E, Caudrelier P, Plotkin S. The place of DTP/eIPV vaccine in routine paediatric vaccination. Rev Med Virol 1994;4:261-77.
20. Prevots DR, Sutter RW, Strebel PM, Wiebel RE, Cochi SL. Completeness of reporting for paralytic poliomyelitis. Arch Pediatr Adolesc Med 1994;148:479-85.
21. Plotkin SA. Inactivated polio vaccine for the United States: a missed vaccination opportunity. Pediatr Infect Dis J 1995;14: 835-9.